‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin. WMJ 2016 Aug;115(4):206-9
Date
08/01/2016Pubmed ID
29099159Scopus ID
2-s2.0-85036614235 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
OBJECTIVE: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, one of a class of novel antiglycemic agents that are gaining in popularity in the treatment of diabetes.
METHODS: We describe a case in which a patient experienced difficult-to-treat metabolic ketoacidosis in the setting of canagliflozin use.
RESULTS: A 52-year-old man with type 2 diabetes mellitus developed profound ketoacidosis without overt hyperglycemia while taking canagliflozin. Despite initiation of an insulin infusion, the metabolic acidosis persisted for 3 days.
CONCLUSION: Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.
Author List
Danford C, Chan P, Magill SBAuthor
Steven B. Magill MD, PhD Staff Physician in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Blood GlucoseCanagliflozin
Diabetes Mellitus, Type 2
Humans
Hypoglycemic Agents
Ketosis
Male
Middle Aged